A JAMA study evaluated use of the YEARS diagnostic algorithm for pulmonary embolism (PE) in cancer patients, reporting similar efficacy to standard computed tomographic pulmonary angiography (CTPA) while cutting the need for invasive imaging in more than one-fifth of cases. The YEARS algorithm is used as a frontline risk-stratification approach for suspected PE. For oncology practices and trial settings, the practical advantage is operational: fewer CTPA scans can reduce procedure-related burden and downstream costs while maintaining diagnostic performance. In cancer patients, who can have overlapping symptoms and higher baseline risk, reliable triage tools are particularly valuable. The key industry takeaway is that diagnostic algorithm refinement is gaining evidence strength in oncology subpopulations. That can influence how hospitals implement PE pathways and may affect how clinical studies define diagnostic standards. The extract does not list the magnitude of safety outcomes, but the headline result emphasizes diagnostic parity with lower imaging utilization.